DF/HCC Calendar
Beth Israel Deaconess Medical Center, Hematology/Oncology Grand Rounds
Speaker: Joan Schiller, MD, Chief, Division of Hematology/Oncology, UT Southwestern Medical Center, Dallas, TX
Presentation: "Updates in the Treatment of Non-small Cell Lung Cancer"
Epidemiology Seminar Series
Wednesday, November 18, 2009
12:30 pm
Speaker: Immaculata De Vivo, M.P.H., Ph.D
Associate Professor, Department of Medicine, Harvard Medical School
Boston, MA
"Telomeres and Chronic Disease"
@ 12:30 PM
Kresge Building Room 502
677 Huntington Avenue
Boston, Massachusetts
Sponsored by DF/HCC and the Epidemiology Department at HSPH
Ixempra
Sprycel
Erbitux
Full Development
Ipilimumab
Brivanib
Tanespimycin
XL-184
Exploratory Development
IGF-R Antagonist
VEGF R-2 Adnectin inhibitor (CT-322)
ErbB/VEGF inhibitor
Anti-CD 137 antibody
Epothilone-Folate
SMO Inhibitor
Cdc7 inhibitor (XL-413)
Anti-CS1 antibody (Elotuzumab)
Adnectin Bispecific inhibitor
RAF Kinase inhibitor (XL-281)
American Association for Cancer Research, Boston Section
Announces the
24th Apffel Memorial Lecture
Thursday, November 19, 2009
3:30-4:30 PM
“Molecular Determinants of Intestinal Differentiation and Tumorigenesis”
Daniel Louvard, Ph.D.
Director, Curie Institute Research Center
Professor, Pasteur Institute
Paris, France
Rabkin Board Room
Shapiro Clinical Center, 10th Floor
Beth Israel Deaconess Medical Center
330 Brookline Ave, Boston, MA
Light reception will follow lecture
Parking
East Campus Main Garage: Located off the main entrance to the medical center's Feldberg Building at 330 Brookline
Avenue; convenient for East Campus buildings. Cashier is located off the lobby of the Feldberg building; customers
pay just before returning to their cars.
The Carl J. Shapiro Clinical Center Garage: Underground garage located on Binney Street, off Longwood Avenue.
Cashier is located on the lobby level of the Shapiro Clinical Center; customers pay just before returning to their cars.
BWH/DFCI Multidisciplinary Neuro-Oncology Conference Presents:
Pursuing potential biomarkers of response and resistance to antiangiogenic therapy: Which ones and why?
Dan G. Duda, DMD, PhD
Assistant Professor of Radiation Oncology
Edwin L. Steele Laboratory for Tumor Biology
Department of Radiation Oncology
Massachusetts General Hospital
Harvard Medical School
Friday, November 20, 2009
11:00am - 11:45am
Pathology Conference Room
Brigham and Women's Hospital
Amory 3
TWO REPRINTS ARE AVAILABLE FOR THIS LECTURE:
1. Antiangiogenics: The Potential Role of Integrating This Novel Treatment Modality With Chemoradiation for
Solid Cancers
2. Biomarkers of response and resistance to antiangiogenic therapy
Please refer to website for reprints: http://www.dfhcc.harvard.edu/
(You may access the reprint by clicking on the DF/HCC calendar icon followed by the DFCI/BWH Multidisciplinary Neuro-Oncology Conference link.)
*Attendance at this lecture will fulfill requirements for 1 hour of AMA PRA category 1 credit, Harvard Medical School, Department of Continuing Education.*
UPCOMING CONFERENCES:
November 20, 2009
CONFERENCE TITLE: Pursuing potential biomarkers of response and resistance to antiangiogenic therapy: Which ones and why?
Dan G. Duda, DMD, PhD
Assistant Professor of Radiation Oncology
Edwin L. Steele Laboratory for Tumor Biology
Department of Radiation Oncology
Massachusetts General Hospital
Harvard Medical School
November 27, 2009
NO CONFERENCE
(Thanksgiving weekend)
December 4, 2009
CONFERENCE TITLE: A synthetic glioma vaccine based on genomic
Peptides
Samuel Bogoch, MD, PhD
Chairman, Foundation for Research on the
Nervous System
Dana-Farber Cancer Institute
Program in Cancer Chemical Biology
Seminar Series
“Biomaterials and biotechnology: From the discovery of
angiogenesis inhibitors to the development of controlled drug
delivery systems and the foundation of tissue engineering”
Robert S. Langer, Sc.D.
David H. Koch Institute Professor
Massachusetts Institute of Technology
Chemical Engineering Department
Cambridge, MA
Abstract
Research starting with the development of novel delivery systems for
macromolecules is discussed. For example, new drug delivery technologies
including nanoparticles and nanotechnology promise to create new treatments
for cancer and other illnesses. They have also been used as essential parts of
the assays used to isolate angiogenesis inhibitors. The creation of new
biomaterials is also discussed. Furthermore, by combining mammalian cells,
including stem cells, with synthetic polymers, new approaches for engineering
tissues are being developed that may someday help repair various tissues.
Thursday, November 19th, 2009
5:00pm
Jimmy Fund Auditorium
Host: Gregory Verdine, Ph.D.
DFCI Tel: 617-632-4502
Dana-Farber/Harvard Cancer Center
A Comprehensive Cancer CenterDesignated by the National Cancer Institute